medigraphic.com

2000, Number 6

Next >>

Arch Cardiol Mex 2000; 70 (6)

Evidence based in Medicine. Science, paradigm or methodology?

Vallejo M, López RMC

Language: Spanish
References: 21
Page: 531-535
PDF size: 79.18 Kb.


Text Extraction

No abstract


REFERENCES

  1. Hayward JA: Historia de la medicina. México IFCE. Cuarta reimpresión 1980: 321.

  2. Benítez-Bribiesca L: Evidence-based medicine: a new paradigm? Arch Med Res 1999; 30: 77-79.

  3. Straus SE, Sackett DL: Getting research findings into practice. Using research findings in clinical practice. Br Med J 1998; 317: 339-342.

  4. Feinstiein RA, Horwitz RI: Problems in the “Evidence” of “Evidence-based Medicine”. Am J Med 1997; 103: 529-35.

  5. Davidoff F: In the teeth of the evidence: the curious case of evidence-based medicine. Mt Sinai J Med 1999; 66(2): 75-83.

  6. Sackett DL, Richardson WS, Rosenberg W, Haynes RB: Evidence-based Medicine. How to practice and teach EBM. London Churchill Livingstone 1997: 250.

  7. Sackett D, Rosenberg WC, Gray JAM, Haynes RB, Richardson WS: Evidence based medicine: what it is and what it isn’t. Br Med J 1996; 312: 71-72.

  8. Muir Gray JA: Atención Sanitaria basada en la evidencia. Cómo tomar decisiones en gestión y política sanitaria. Madrid. Churchill Livingstone 1997: 302.

  9. Rosemberg W, Donald A: Evidence based medicine: an approach to clinical problem solving. Br Med J 1995; 310: 1122-26.

  10. López-Jiménez F, Lams GA: Evidence-based medicine. Arch Med Res 1999; 30: 80-81.

  11. Hirsh J, Fuster V: Guide to anticoagulant therapy. Part I: Heparin. American Heart Association. Circulation 1994; 89(3): 1949-68.

  12. Lane DA, Pejier G, Flynn AM, Thompson EA, Lindahi U: Neutralization of heparin-related saccharides by histidine-rich glicoprotein and platelet factor 4. J Biol Chem 1986; 261(9): 3980-6.

  13. Hirsh J, Levine MN: Low molecular weigth heparin. Blood 1992; 79: 1-17.

  14. Howard PA: Deltaparin a low-molecular-weight heparin. Ann Pharmacother 1997; 31: 192-203.

  15. Antman EM, Mc Cabe CH, Grunfinkel EP, Turpie AG, Bernink PJ, Salein D, et al: Enoxaparin prevents death and cardiac ischemic events in unstable angina/non Q wave myocardial infarction. Results of the thrombolysis myocardial infarction (TIMI) 11B trial. Circulation 1999; 1000(15): 1593-601.

  16. The FRAX.I.S. study group. Comparison of two treatment duration (6 day and 14 days) of a low molecular weight heparin with a 6 days treatment of unfraction heparin in the initial management of unestable angina or non-Q-wave myocardial infarction: FRAX.I.S. (fraxiparine in ischemic syndrome). Eur Heart J 1999; 20(21): 1553-62.

  17. Goodman S, Bigonzi F, Radley D: One year follow up of the ESSENCE trial (enoxaparin versus heparin in unstable angina and NQMI). Eur Heart J 1998; 19(Suppl): 477.

  18. Antman EM, Fox KM: Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: proposed revision. International Cardiology Forum. Am Heart J. 2000; 139(3): 461-475.

  19. Calva MJJ, Ponce de León RS, Vargas VF: Cómo leer revistas médicas. Rev Invest Clin 1988; 40(1): 65-106.

  20. Cilisk F, DiCenso DL, Cullum N: Centers of evidence-based nursing: directions and challeges. Evidence-based Nursing 1999; 2(4): 102-104.

  21. Ellis J, Mulligan I, Rowe J, Sackett DL: Inpatient general medicine in evidence based. Lancet 1995; 346: 407-410.




2020     |     www.medigraphic.com